- 2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
- 2seventy bio to Participate in Upcoming Investor Conferences
- 2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
- 2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
Key statistics
As of last trade, 2Seventy Bio Inc (TSVT:NSQ) traded at 4.57, 197.71% above the 52 week low of 1.54 set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.50 |
---|---|
High | 4.62 |
Low | 4.47 |
Bid | 4.55 |
Offer | 4.57 |
Previous close | 4.55 |
Average volume | 674.08k |
---|---|
Shares outstanding | 51.41m |
Free float | 49.66m |
P/E (TTM) | -- |
Market cap | 245.20m USD |
EPS (TTM) | -4.34 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 16:36 BST.
More ▼